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Abstract 
Unfractionated heparin (UFH) is the most widely used interdialytic lock solution but has no anti‑infectious proper‑
ties. Ethanol at a content ≥40 %v/v eradicates experimental biofilm but has no anticoagulant properties. In contrast 
to UFH, enoxaparin (Enox) can be combined with 40 % ethanol without precipitation. Enoxaparin 400 UI/mL–40 % 
ethanol (Enox/Eth) has antibiofilm properties and therefore has promise as an alternative lock solution. This study 
assessed the anticoagulant properties of Enox/Eth. Enox and Enox/Eth were diluted in whole blood at a final Enox 
concentration of 0.5, 1 (N = 6 samples), 1.5 (N = 4) and 2 (N = 6) IU/mL. Anti‑Xa activity was determined by chromo‑
genic assay and the inhibition of endogenous thrombin potential (ETP) by thrombinography. Quantitative data were 
compared by the Mann‑Withney U test. For Enox concentrations of 0.5, 1, 1.5 and 2 UI/mL in whole blood samples, 
the mean ± SD values of the anti‑Xa activity were 0.68 ± 0.09, 1.26 ± 0.14, 1.73 ± 0.30, 2.35 ± 0.32 UI/mL for Enox/
Eth and 0.94 ± 0.15, 1.80 ± 0.22, 2.74 ± 0.23, 3.54 ± 0.44 UI/mL for Enox (P = 0.03, P = 0.03, P = 0.13, P = 0.03); and 
of the percentage of ETP inhibition was 17.36 ± 9.65, 30.27 ± 17.06, 36.5 ± 17.06, 57.82 ± 15.42 for Enox/Eth, and 
42.96 ± 15.68, 68.93 ± 10.01, 83.5 ± 8.81, 91.19 ± 4.67 for Enox (P = 0.03, P = 0.03, P = 0.13, P = 0.03), respectively. 
The median and IQR values of Enox concentration inhibiting 50 % of ETP (IC50 ETP) were 1.8 [1.1–2.4] IU/mL for Enox/
Eth and 0.7 [0.3–0.9] IU/mL for Enox, P = 0.03. Enox/Eth has strong anticoagulant activity, albeit lower than that of 
Enox, but with an extremely low IC50 ETP compared to the Enox concentration of non‑diluted Enox/Eth.
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Background
Central venous catheters are increasingly used for long-
term vascular access in end stage renal disease patients 
with limited access for hemodialysis. The main compli-
cations related to hemodialysis catheter use are infec-
tion and thrombosis. Interdialytic catheter locking with 
unfractionated heparin (UFH) is routinely performed to 
maintain catheter patency (Jain et  al. 2009; Moran and 
Ash 2008). UFH has no anti-infectious properties and 
despite its widespread use as interdialysis lock solution, 
catheter infection remains a major complication entail-
ing substantial morbidity, mortality, and additional costs. 
Antibiotic locking reduces the rate of catheter infection 
(Zhao et  al. 2014) but is not recommended because it 
promotes bacterial resistance (Landry et al. 2010; Dixon 
et al. 2012).
Ethanol is a wide spectrum antimicrobial agent that 
acts by protein denaturation with little risk of the emer-
gence of resistant organisms. A preliminary randomized 
controlled trial involving chronic dialysis patients sug-
gested that 70  %v/v ethanol locking administered once 
a week could be effective in reducing catheter infection 
(Broom et  al. 2012). Exposure of intravascular devices 
to high concentrated ethanol poses questions about 
its effect on the structural stability and the mechanical 
properties of catheters (Guenu et al. 2007; Msakni et al. 
2013; Mermel and Alang 2014). In contrast, immers-
ing catheters in 40  %v/v ethanol has only a marginal 
impact on catheter integrity (Msakni et  al. 2013). No 
clinical study has evaluated the efficacy of 40 % ethanol 
lock in preventing catheter infection. However, ethanol 
at content ≥40 % (v/v) exerts antibiofilm effects against 
most microorganisms commonly involved in catheter 
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infections (Balestrino et al. 2009; Lesens et al. 2013; Öncü 
2014) and, therefore, 40 % ethanol could be an attractive 
antimicrobial agent for lock solution.
However, ethanol has no anticoagulant properties and 
so the optimal lock solution could be a mixture of hepa-
rin and ethanol. Unfortunately, UFH cannot be combined 
with 40 % ethanol because of precipitation (Lartigue et al. 
2015). By contrast, low molecular weight heparins can 
be combined with 40 % ethanol depending on their con-
centrations, and of these, enoxaparin (Enox) exhibits the 
highest solubility in 40  % ethanol (Lartigue et  al. 2015). 
A mixture of Enox 400 UI/mL–40 % ethanol (Enox/Eth) 
has an antibiofim activity similar to that observed with 
40  % ethanol alone and has only a marginal impact on 
silicone and polyurethane catheter integrity (Balestrino 
et al. 2015). Thus, Enox/Eth could be an attractive alter-
native interdialytic lock solution. Whether Enox/eth has 
persistent anticoagulant properties, however, remains 
unknown. The purpose of this study was to assess the 
anticoagulant activity of Enox/eth.
Methods
Mixtures
The solutions were prepared on the day before the 
test. Enox 400  IU/mL was prepared with Enox sodium 
(Lovenox® 4000  IU/0.4  ml, Sanofi-Aventis, France) 
diluted in 0.9  % sodium chloride (Aguettant, Lyon, 
France), 40 %v/v ethanol with 99 % ethanol (Carlo Erba, 
Peypin, France) diluted in 0.9  % sodium chloride, and 
Enox/Eth with Enox 400  IU/mL diluted in ethanol and 
0.9  % sodium chloride. The density of Enox/Eth deter-
mined at room temperature (23  °C) by specific gravity 
bottle (pycnometer) according to the European Phar-
macopeia recommendations (6.0 (01/2008:20205) was 
0.9498.
On the day of the test, venous blood from 6 blood 
donors, 4 women and 2 men, was collected into Vacu-
tainer tubes (Becton–Dickinson, Meylan Cedex, France) 
containing 0.129  M sodium citrate (1 vol anticoagulant 
and 9 vol whole blood). The first 2–3 ml of whole blood, 
which could potentially be contaminated by tissue fac-
tor present in the skin or vascular cells, were discarded. 
The samples were analyzed within 2  h of collection as 
recommended.
Enox 400  IU/mL was added to whole blood to obtain 
blood samples with enoxaparin concentrations of 0.5, 1, 
1.5 and 2 IU/mL; 40 % ethanol was added to whole blood 
to obtain blood samples with ethanol contents of 0.05, 
0.1, 0.15 and 0.2 %v/v; and Enox/Eth was added to whole 
blood to obtain blood samples with enoxaparin concen-
trations/ethanol contents of 0.5/0.05, 1/0.1, 1.5/0.15 and 
2/0.2 IU/mL/ %v/v. The control was prepared by mixing 
0.9 % sodium chloride with whole blood.
All mixtures were prepared in polypropylene tubes and 
then incubated 1  h at 37  °C with gentle shaking every 
10  min to mimic in  vivo conditions of catheter lumen. 
They were subsequently centrifuged at 200xg, for 10 min 
at 20 °C to obtain platelets rich plasma (PRP), which were 
immediately used for thrombinography assays. Plate-
let poor plasma (PPP) were obtained by centrifugation 
(twice at 2500g for 15  min) and stored at −80  °C until 
anti-Xa assays.
Anticoaguant activity
The anticoagulant properties were assessed by measure-
ment of both antithrombotic activity and anti Xa activity.
Antithrombotic activity
All assays were performed in triplicate. Antithrombotic 
activity was determined by measurement of thrombin 
generation (TG) by thrombinography as described else-
where (Tardy-Poncet et  al. 2009). Recombinant human 
tissue factor (Innovin) was purchased from Dade Behring 
(Marburg, Germany), fluorogenic substrate, Z-Gly-
Gly-Argaminomethylcoumarin (Z-GGR- AMC) from 
Bachem (Weil am Rhein, Germany), thrombin calibrator 
from Diagnostica Stago (Asnières, France), 96-round bot-
tom well microplates from Dutscher Greiner (Brumath, 
France) and Bovine serum albumin (BSA) from Sigma (St 
Quentin Fallavier, France). Thrombogram software was 
supplied by Synapse (Maastricht, The Netherlands).
Twenty microlitre of diluted tissue factor (final dilution 
1/1200) in HBS buffer (Hepes 20  mM, NaCl 140  mM, 
BSA 5  g/L, pH 7.35) were dispensed into the wells. 
Twenty µL of thrombin calibrator were added to the cali-
brant wells. Eighty µL of each fresh PRP mixture were 
then placed in the wells. The plate was inserted into a 
Fluoroskan Ascent plate reader (Thermolab Systems, 
Helsinki, Finland) and preheated to 37  °C for 10  min. 
Coagulation was triggered by the automated addition 
of 20 µL of Z-GGR-AMC (2.5 mM) dissolved in 20 mM 
Hepes buffer (pH 7.35) containing 0.1 M CaCl2 and 60 g. 
L-1 BSA. The plate was then shaken for 12  s. Fluores-
cence intensity was determined at wavelengths of 390 nm 
(excitation filter) and 460 nm (emission filter) every 15 s 
during 60  min. TG was monitored continuously using 
the calibrated thrombogram method described by Hem-
ker et al. (2003), in which the initial derivative curves of 
fluorescence accumulation are converted into TG curves 
using a human thrombin calibrator and Thrombinoscope 
software (version 3.0.25; Biodis, Signes, France).
Thrombinography was performed on PRPs containing 
40  % ethanol, Enoxaparin, and Enox/Eth. The following 
thrombogram parameters were measured: lag-time (LT, 
min), thrombin peak (TP, nmol thrombin), endogenous 
thrombin potential (ETP, nmol*min) which corresponds 
Page 3 of 8Calvet et al. SpringerPlus  (2015) 4:746 
to the area under the curve, time to peak (ttP, min) and 
velocity index, which corresponds to the propagation 
phase of thrombin generation calculated by the formula 
TP/(ttP-LT). The anti-thrombotic effect of the different 
mixtures was expressed in percentage of ETP inhibition 
(ETP(basal) − ETP (solution tested)/ETP(basal) × 100). 
IC50 ETP was defined as the concentration of a solution 
inhibiting 50 % of ETP and represents classically the con-
centration required to achieve adequate anticoagulation 
(al Dieri et al. 2004).
Anti‑Xa activity
Enox anti-Xa activity was measured on PPP. The assays 
were performed on an automated coagulometer BCS 
(Siemens, France), using an anti-Xa chromogenic assay 
(Biophen Heparin, Hyphen BioMed, Neuville sur Oise, 
France) according to the specific recommendations of 
Hyphen Biomed. The persistency of the anti-Xa activity 
of Enox 400 UI/ml and Enox/Eth at the final Enox con-
centration of 1 IU/mL was assessed in one donor PPP at 
30 min, 23 h, 46 h, 119 h and 216 h.
Statistical analysis
Results were expressed as mean  ±  standard deviation 
(SD) or median and interquartile ranges (IQR). Quantita-
tive data of the different solutions were compared by the 
Man-Withney U test, and anti Xa activity and ETP inhi-
bition by Spearman correlation. Statistical analyses were 
carried out with Statview 5.0 software (SAS Institute, 
Cary, NC, USA). A p value ≤0.05 was considered statisti-
cally significant.
Ethics statement
Human blood samples used in this study came from 6 
healthy donors at the local French Blood Service [Etab-
lissement Français du Sang, Saint-Etienne]. After being 
fully informed as required by the Public Health Code 
(article R.1221-5, decrees of 01/12/2009 and 06/11/2006), 
all donors involved in our study gave written consent.
Results
The mean basal value of ETP in the controls was 
1730 ± 325 nmol*min. TG measured in PRP from whole 
blood samples at ethanol contents of 0.05, 0.1, 0.15 and 
0.2  %v/v was similar to TG in controls, demonstrating 
that ethanol alone at these low concentrations has no 
impact on the antithrombotic activity (data not shown).
Enox/Eth at Enox concentrations between 0.5  IU/
mL and 2.0  IU/mL was associated with a 15–54  % ETP 
inhibition (Table 1, Fig. 1). For each Enox concentration, 
ETP inhibition of Enox/Eth was lower than that observed 
with Enox (Fig.  2). IC50 ETP median and IQR values 
were 1.8 [1.1–2.4] IU/mL for Enox/Eth and 0.7 [0.3–0.9] 
IU/mL for Enox, P = 0.03. Lower ETP inhibition values 
and therefore higher IC 50 ETP values were observed 
in females than in males for both Enox/Eth and Enox 
(Fig. 3).
Table 1 Results of  the inhibition of  endogenous throm-
bin potential (ETP) induced by enoxaparin (Enox) and the 
mixture of  enoxaparin 400  IU/mL–40  % ethanol (Enox/
Eth) measured on  platelet rich plasma by  thrombinog-
raphy according to  Enox concentration in  whole blood 
from donors
Enox enoxaparin, Enox/Eth enoxaparin 400 IU/mL–40 % ethanol
a Concentration in whole blood
b In percentage and expressed as mean ± standard deviation





0.5 (N = 6) 42.96 ± 15.66 17.36 ± 9.65 0.03
1 (N = 6) 68.93 ± 10.01 30.27 ± 17.06 0.03
1.5 (N = 4) 83.5 ± 8.81 36.5 ± 17.06 0.13









































Fig. 1 Representative thrombin generation curves from an individual 
blood donor measured in PRP, after whole blood incubation for 1 h 
à at 37 °C with: a Enox (blood concentration 0.5–2.0 IU/m/L), and b 
Enox/Eth (blood concentration 0.5–2.0 IU/m/L) Thrombogram param‑
eters—Lag‑time (min): initiation phase of thrombin generation; Peak: 
maximal concentration (Cmax) of thrombin generated, expressed in 
nM; Time to peak (TtPeak time in min) necessary to achieve maximal 
thrombin concentration (Tmax); Endogenous thrombin potential 
(ETP): (nMxmin) area under the curve (represents thrombin molecule 
activity in plasma); Start‑Tail: time (min) to at the term of which the 
curve of the thrombogram returns to zero
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The anticoagulant effect of Enox in Enox/Eth was 
demonstrated with the Anti-Xa tests in all PPP samples 
with a correlation between whole blood Enox concen-
tration and anti-Xa activity (Table  2). For each whole 
blood Enox concentration, there was a mean decrease 
of 26.7–36.7 % in the anti-Xa activity of PPP with Enox/
Eth as compared to PPP with Enox alone. The anti-Xa 
activity ratio of PPP with Enox to PPP with Enox/Eth 
was stable over time: 1.02 at 30 min, 0.83 at H23, 0.82 
at H 46, 0.85 at H 119, and 0.82 at H 216 (one sample 
tested).
We further investigated the relation between anti-Xa 
activity and ETP. Plotting ETP inhibition against anti-Xa 
activity showed a strong relation between the increase in 
ETP inhibition and the increase in the anti-Xa activity for 
Enox/Eth (P = 0.04) and Enox alone (P < 0.0001), (Fig. 4). 
For Enox alone, there was a sharp increase in inhibition 
at low Enox activity that approached complete inhibition 
when the anti-Xa activity was >2.5 IU/mL. For Enox/Eth, 
Fig. 4 displays a similar pattern, suggesting a hyperbolic 
relationship between ETP and anti-Xa activity and com-
plete inhibition, but at higher values than those observed 
for Enox alone.
Discussion
Our study adds important information regarding the 
anticoagulant properties of Enox/Eth by demonstrating 
both its antithrombotic and anti-Xa activity.
Most studies on the in  vitro properties of catheter 
lock solutions containing both injectable anticoagulants 
and antimicrobials have focused on mixtures of heparin 
with antibiotics, and are limited to their chemical stabil-
ity and antimicrobial properties (Krishnasami et al. 2002; 
Droste et  al. 2003; Anthony and Rubin 1999; Vercaigne 
et  al. 2000, 2002; Capdevila et  al. 2001). The stability of 
Enox/Eth may be questionable since mixing ethanol with 
heparin may result in heparin precipitation. The assess-
ment of Enox/Eth solubility by visual observation showed 
that the mixture remained clear for up to 72 h of incuba-
tion at room temperature (23 °C) and at 37 °C. The stabil-
ity of Enoxaparin 400 IU/mL and that of 40 % ethanol in 
Enox/Eth was confirmed by the HPLC-ELSD method and 
by a titrimetric dichromate assay, respectively (Lartigue 
et al. 2015). In vitro studies have shown that high concen-
trated ethanol exposure induces changes in the structural 
stability of polyurethane catheters and to a lesser extent 
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Fig. 3 IC50 ETP of Enox/Eth and Enox: inter‑individual and sex related variability. M men donors, F women donors
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2013) and may result in catheter occlusion and breaches 
(Mermel and Alang 2014). However, immersing cath-
eters in 40 % ethanol or in Enox/Eth has only a marginal 
impact on polyurethane catheter integrity (Msakni et al. 
2013; Balestrino et  al. 2015), which suggests that Enox/
Eth ethanol has only a minimal effect on the mechanical 
properties of catheters.
Ethanol solutions at a concentration above 28 % can be 
associated with plasma protein precipitation (Schilcher 
et  al. 2013). In our in  vitro study, we did not assess the 
impact of Enox/Eth on plasma protein in a clinical setting 
and we did not analyze the spillage of Enox/Eth or the 
leakage of potentially precipitated protein particles into 
the systemic circulation. However, a previous experimen-
tal study showed that heparins inhibit the precipitation 
of plasma proteins (Pemberton et al. 2010). In addition, 
Enox/Eth has a lower density than blood and plasma 
(Trudnowski and Rico 1974), which suggests that Enox/
Eth leakage into the systemic circulation followed by the 
entry of blood into the catheter would be negligible, par-
ticularly for catheters inserted at the jugular sites. Taken 
together, these data suggest that marked plasma protein 
precipitation due to spillage of Enox/Eth is unlikely.
The anticoagulant activity of these catheter lock solu-
tions has been scarcely reported and mainly assessed by 
clotting tests (Robinson et  al. 2005; Cullis et  al. 2015). 
However, clotting time assays only probe the initiation 
phase of coagulation by measuring the time before the 
burst of thrombin starts and generates clot. The determi-
nation of the amount of thrombin activity that develops 
could be a better marker of the function of the clotting 
system. Thrombinography is a global test that meas-
ures the ability of a plasma sample to generate throm-
bin after in vitro initiation of coagulation. It reflects the 
initiation, propagation and termination phases of the 
coagulation, and therefore takes into account the pro and 
anticoagulant reactions governing thrombin formation. It 
is a suitable assay to measure the anticoagulant activity 
Table 2 Results of  the Anti Xa activity induced by  enoxa-
parin (Enox) and  the mixture of  enoxaparin 400  IU/
mL–40  % ethanol (Enox/Eth) measured on  platelet rich 
plasma by thrombinography according to Enox concentra-
tion in whole blood from donors
Enox enoxaparin, Enox/Eth enoxaparin 400 IU/mL–40 % ethanol
a Concentration in whole blood
b In IU/mL and expressed as mean ± standard deviation
Enox (IU/mL)a Anti Xa activity 
of Enoxb
Anti Xa activity 
of Enox/ethb
P value
0.5 (N = 6) 0.94 ± 0.15 0.68 ± 0.09 0.03
1 (N = 6) 1.80 ± 0.22 1.26 ± 0.14 0.03
1.5 (N = 4) 2.74 ± 0.23 1.73 ± 0.31 0.13
2 (N = 6) 3.54 ± 0.44 2.35 ± 0.32 0.03




















Fig. 4 Inhibition of the endogenous thrombin potential (ETP) as a function of Anti Xa enoxaparin activity in poor platelet plasma
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of anticoagulant drugs and particularly that of enoxapa-
rin (al Dieri et al. 2004; Hemker et al. 2002; Gerotziafas 
et al. 2004; Robert et al. 2009). ETP is the area under the 
thrombin generation curve and is considered the most 
robust parameter of the thrombogram (TG curve) for 
estimating the total amount of thrombin formed over 
time (Al Dieri et al. 2012). To our knowledge, our study is 
the first to use thrombinography to assess the antithrom-
botic effect of a lock solution.
Numerous studies have assessed the hemostatic prop-
erties of ethanol owing to the association between light 
to moderate alcohol drinking and a lower incidence of 
ischemic heart disease resulting from suppression of 
thrombus formation and atherosclerotic progression, and 
a higher bleeding tendency (Mukamal et al. 2003). Etha-
nol inhibits platelet aggregation and impairs fibrinoly-
sis (Marumo and Wakabayashi 2010; Engström et  al. 
2006; Ehrlich and Humpel 2014). The results of stud-
ies reporting the impact of ethanol on the coagulation 
vary according to the experimental conditions and the 
tests used (Engström et  al. 2006; Bloemen et  al. 2012). 
In preliminary tests, we found that ethanol at contents 
ranging between 0.05 and 0.2 %v/v had no effect on TG 
parameters either at room temperature or at 37 °C. Simi-
lar results have already been published (Bloemen et  al. 
2012). In contrast, we found that when ethanol is mixed 
with Enox at Enox concentrations/ethanol contents of 
0.5/0.05, 1/0.1, 1.5/0.15 and 2/0.2  IU/mL/%v/v, ethanol 
diminishes the antithrombotic effect of enoxaparin by 
two-thirds by decreasing IC50 ETP from 1.8 IU.mL-1 for 
Enox/Eth to 0.7 IU.mL-1 for Enox alone. The cause of the 
diminished antithrombotic effect of Enox when Enox is 
mixed with ethanol is speculative, but we cannot exclude 
that platelet exposed to ethanol shed PF4 results in a 
decrease in enoxaparin activity.
In our study we observed an inter-individual variability 
in the antithrombotic effect of Enox and Enox/Eth. Large 
variation in TG response to heparin between individuals 
and low molecular weight heparin for the same anti-Xa 
level is classically reported and probably reflects inter-
individual variability in baseline coagulation potential 
(Cullis et  al. 2015; Hemker et  al. 2002; Chowdary et  al. 
2015). We also observed lower ETP inhibition in females 
than in males in response to both Enox and Enox/Eth. 
Differences in TG values according to gender, with higher 
ETP in women, have already been reported (Marchi et al. 
2015). Lower susceptibility of women to heparin has been 
suggested by in vitro experiments using thromboelastog-
raphy (Monte and Lyons 2004).
The decreased antithrombotic effect of Enox/Eth com-
pared to that of Enox alone and the gender variability 
that we observed have probably only a marginal impact 
on the anticoagulant properties of Enox/Eth, since Enox 
concentration in Enox/Eth is more than 200-fold higher 
than the concentration used in our experiments.
The dilutions of Enox used in this study are representa-
tive of clinical practice. When measuring Enox anti-Xa 
activity in PPP, we found higher values than in whole 
blood. This makes sense because the volume of blood 
is larger than the volume of PPP, and the total amount 
of Enox in both whole blood and PPP was equivalent 
(very little Enox being sequestrated in red blood cells). 
The results of the anti Xa tests shows that for each Enox 
concentration, the anti-Xa activity of Enox/Eth was 
decreased by approximately one-third as compared to 
Enox alone. As mentioned above in the TG results, the 
discrepancy in the anti-Xa activity between Enox alone 
and Enox/Eth is probably only marginal because of the 
extreme dilution of Enox/Eth in the samples. Further-
more, the decrease in the anti-Xa activity of Enox/Eth 
was observed in the first 24 h, with no further decrease 
up to 216 h afterwards, suggesting that Enox/Eth instilled 
in a catheter for a dwell time of 48 to 72 h could exert its 
anti-Xa activity during the entire interdialytic period.
Our study presents some limitations. First, the 
antithrombotic properties of Enox/Eth were investigated 
in a small sample of 6 Caucasians (4 women and 2 men) 
and revealed inter-individual variability in the antithrom-
botic effect but all individual results follow the same 
trend and show an anticoagulant effect of the mixture. 
However, whether the results can be applied to a non-
Caucasian population is speculative and would require 
further large-scale studies. Second, blood used in the 
study was obtained from healthy adult donors, and not 
from chronic dialysis patients. Possible alterations in the 
anticoagulant status of end stage renal disease patients 
might affect hemostasis tests and yield different results. 
However, previous studies using thrombinography 
reported the presence of hypocoagulability in chronic 
dialysis patients (Jeong et  al. 2013; Brophy et  al. 2006), 
which suggests that the strong anticoagulant activity of 
Enox/Eth observed with blood from healthy adult donors 
would not have been diminished if we had used blood 
from chronic dialysis patients. Third, as is standard in 
this kind of test, the experiments were performed using 
polypropylene tubes, whereas in a clinical setting the lock 
solutions are instilled into polyurethane or silicone cathe-
ters. We cannot exclude that the anticoagulation proper-
ties of lock solutions observed in the polypropylene tubes 
may be modified when the solution is exposed to other 
materials. Fourth, the conditions of this in  vitro-study 
differ widely from those of the clinical setting. In particu-
lar, they do not take into account the seepage of the lock 
solution into the systemic circulation, which is accom-
panied by a concomitant blood inflow into the catheter. 
The leakage of catheter lock solutions may dilute the lock 
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solution and favor plasma protein precipitation by the 
high ethanol content contained in Enox/Eth (Schilcher 
et al. 2013).
Conclusion
In conclusion, Enox/Eth exerts strong anticoagulant 
activity. We previously demonstrated the stability of 
Enox/Eth (Lartigue et  al. 2015), its low impact on poly-
urethane and its antibiofilm activity against the micro-
organisms commonly involved in catheter infections 
(Balestrino et  al. 2015). Taken together these findings 
suggest that Enox/Eth may be a suitable catheter lock 
solution for preventing catheter infection and maintain-
ing catheter patency. A large randomized control trial is 
now warranted to assess the efficacy of Enox/Eth in pre-
venting dialysis catheter infection in chronic hemodialy-
sis patients.
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